Emerging Clinical Trial Locations:

Market dynamics and the changing healthcare and regulatory environment

This report provides a comprehensive examination of the clinical trial landscape in emerging countries, with specific focus on China, India, Central and Eastern Europe and Latin America. It identifies the major drivers and barriers to conducting clinical trials in emerging regions and profiles key issues for consideration when selecting a trial site.

Claim "10% Discount for Farmavita.Net Members" when purchasing this report!

Russia is one of the world leaders in patient enrolment - the average patient recruitment rate in 2006 exceeded 4.7 patients per site per month. For some nosologies, this figure is 10 times higher than in Western Europe and the US.

The Chinese CRO market was valued at $250m in 2008. The market is expected to grow at a CAGR of 33% over the next four years to reach $791m in 2012. By that time, Chinese CROs will account for an estimated 2.3% of the global CRO market.

The costs of conducting clinical trials in Latin America vary from substantially less expensive than the US to slightly more expensive. In recent trials, the cost per patient for Latin America has varied from savings of 50% to relative cost increases against US per patient costs.

Claim "10% Discount for Farmavita.Net Members" when purchasing this report!


Share this post

Submit to FacebookSubmit to Google PlusSubmit to TwitterSubmit to LinkedIn